The vesicular monoamine transporter 2 (VMAT2) is an integral presynaptic protein that regulates the packaging and release of dopamine and other monoamines from neuronal vesicles into the synapse.  Dopamine dysregulation is closely associated with the development of various movement disorders, with dopaminergic hyperactivity being linked to hyperkinetic movement disorders (e.g., tics, tremor, myoclonus, chorea, dystonia) and reduced dopaminergic activity to hypokinetic states (e.g., Parkinson’s disease). Here we describe the discovery and characterization of Ingrezza (valbenazine) a novel VMAT2 inhibitor that was recently approved for tardive dyskinesia.

Discovery and characterization of ingrezza (valbenazine): A VMAT2 inhibitor approved for the treatment of tardive dyskinesia

255th National Meeting (2018)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.